According to clinical trials, Gemtesa (vibegron) has an effective half-life of 30.8 hours. The median time to maximum plasma concentration is around 1 to 3 hours. In terms of route of elimination, following a radiolabeled dose, only about 59% of the dose was received in feces and 20% in urine. Total terminal plasma half-life ranges anywhere from 50 to 70 hours per patient. Or roughly two to three days.
Key Takeaways
Total terminal plasma half-life for Gemtesa (vibegron) is anywhere from 50 hours to 70 hours depending on the patient. A patient's metabolic rate may have a large impact on the terminal plasma half-life period.
The absorption period of Gemtesa (vibegron) is around 1 to 3 hours post-oral administration. Playing some role in the total terminal plasma half-life range, however, not a significant amount compared to other medications.
The total days that Gemtesa (vibegron) may stay in your system is anywhere from two to three days.
How Long Does Gemtesa (Vibegron) Stay In Your System?
Gemtesa (viebron) has a total elimination (or half-life) time of about 30.8 hours. However, the total amount of time that Gemtesa (vibegron) may stay in your system (or total terminal plasma half-life) is about 50 hours or about two-days.
Parameter | Details |
Drug Name | Vibegron (Gemtesa) |
Half-life (t½) | Approximately 50 hours |
Absorption | Tmax (time to maximum concentration): 1–3 hours post-oral administration |
Steady State Achievement | Typically achieved within 7 days of once-daily dosing |
Elimination Pathways | Predominantly excreted via feces (~59%) and urine (~20%) |
The half-life (t1/2) of a drug like Gemtesa (vibegron) is calculated based on its elimination kinetics, typically derived from pharmacokinetic studies from the clinical trials.
Other factors such as your body’s natural ability to metabolize medications may play a pivotal role in how long Gemtesa (vibegron) is in your system. CYP3A4 is the predominant enzyme responsible for in vitro metabolism. And can vary patient by patient.
Find Affordable Brand-Name and Generic Drugs at Drugmart.com At Drugmart.com, we pride ourselves on our affordability, exceptional quality and ease of use when our patients shop for both brand-name and generic drugs. We work closely with the world's most reputable pharmacies to provide high-quality medications from Canada and other tier 1 international sources at unmatched prices, so you can get the treatment you need without worrying about affordability.
Sources
U.S. Food and Drug Administration. (n.d.). Drug trials snapshot: Gemtesa. Retrieved November 15, 2024, from https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-gemtesa
Urovant Sciences. (2020). Gemtesa prescribing information. Retrieved November 15, 2024, from https://www.gemtesa.com/files/gemtesa-prescribing-information.pdf
The Medical Letter. (2023). Vibegron (Gemtesa) for overactive bladder. The Medical Letter on Drugs and Therapeutics, 62(1623). Retrieved November 12, 2024, from https://secure.medicalletter.org/system/files/private/TML-article-1623c.pdf
U.S. Food and Drug Administration. (2020). Original NDA approval for Gemtesa (NDA 213006). Retrieved November 15, 2024, from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000Approv.pdf
Sumitomo Pharma. (2023). Notice regarding approval of vibegron (generic name) in China for overactive bladder treatment. Retrieved November 13, 2024, from https://www.sumitomo-pharma.com/news/assets/pdf/ene20230912.pdf